Fluor Corporation Common Stock vs GE HealthCare Technologies Inc. Common Stock — how do they compare? Fluor Corporation Common Stock trades at $47.02 (market cap $6.65B), while GE HealthCare Technologies Inc. Common Stock trades at $68.97 (market cap $31.07B). The key difference: GE HealthCare Technologies Inc. Common Stock is far larger — about 4.7× Fluor Corporation Common Stock's market cap, and GE HealthCare Technologies Inc. Common Stock pays a 0.23% dividend while Fluor Corporation Common Stock pays none. Which is the better fit depends on your goals.
| FLR | GEHC | |
|---|---|---|
Market Cap | $6.65B | $31.07B |
Volume | 1,556,536 | 3,443,020 |
Sector | Industrials | Health |
52-Week High | $57.50 | $88.16 |
52-Week Low | $39.63 | $59.48 |
Typical Hold Time | 6 Days | — |
Enterprise Value | $4.68B | $39.53B |
Dividend Yield | — | 0.23% |
Signals from Pluang's Aura AI — not financial advice
Fluor Corporation (FLR) trades at $49.75, showing minimal daily movement with a 0.08% gain. The stock faces bearish technical signals but maintains analyst support with a $62.33 consensus price target. Recent Q2 2026 earnings beat expectations, though profitability remains challenged with negative margins. The company secured a significant $7.5 billion LNG Canada Phase 2 project, providing substantial future revenue visibility amid ongoing operational restructuring.
FLR presents a turnaround opportunity with strong backlog coverage but carries execution risks. The stock trades at attractive valuation multiples (P/S 0.49) with 53.6% analyst buy ratings, yet negative cash flow and margin pressures require careful monitoring. Near-term performance hinges on successful project execution and margin improvement from the shift to reimbursable contracts.
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Trailing returns across standard periods
Fluor provides engineering, procurement, construction, and maintenance services. It works across energy, infrastructure, mining, advanced technology, manufacturing, life sciences, and government projects.
Read more on FLR →GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →